Stay updated on PEMBRACA: Pembrolizumab+Carboplatin in Breast Cancer Antigens Clinical Trial
Sign up to get notified when there's something new on the PEMBRACA: Pembrolizumab+Carboplatin in Breast Cancer Antigens Clinical Trial page.

Latest updates to the PEMBRACA: Pembrolizumab+Carboplatin in Breast Cancer Antigens Clinical Trial page
- Check7 days agoNo Change Detected
- Check15 days agoChange DetectedRevision label on the page updated from v3.6.3 to v3.6.4, indicating a recent deployment/maintenance update to the page.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check29 days agoNo Change Detected
- Check36 days agoChange DetectedThe revision label on the page changed from v3.6.2 to v3.6.3, signaling a new version of the page. This likely represents maintenance or minor updates rather than changes to the study details.SummaryDifference0.1%

- Check43 days agoChange DetectedFooter revision badge updated from v3.6.0 to v3.6.2. This indicates a newer page template/version without altering the displayed study details or workflow.SummaryDifference0.1%

- Check57 days agoChange DetectedThe page adds a recruitment-status note 'No longer looking for participants', indicating recruitment has ended. It also updates navigation/help sections (How to Read a Study Record, Common Questions, How to Join a Study), adjusts the Intervention/Treatment heading formatting, and adds a footer revision note 'Revision: v3.6.0'.SummaryDifference0.5%

- Check65 days agoChange DetectedThe page footer now displays Revision: v3.5.5, replacing Revision: v3.5.4. This indicates a minor update to the study record page without altering core content.SummaryDifference0.1%

- Check86 days agoChange DetectedRevision label updated to v3.5.4, indicating deployment of a new page version that replaces the previous v3.5.3.SummaryDifference0.1%

Stay in the know with updates to PEMBRACA: Pembrolizumab+Carboplatin in Breast Cancer Antigens Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PEMBRACA: Pembrolizumab+Carboplatin in Breast Cancer Antigens Clinical Trial page.